Clara Burtenshaw, Neo Kuma Ventures, on shattering the stigma of psychedelic medication

The Pulse by Wharton Digital Health

In this episode, we sat down with Clara Burtenshaw, Clara is a biotech and life sciences investor with significant transactional, VC, IP, and operational experience. We discussed: -The evolution of the psychedelics industry from a stigmatized counterculture phenomenon to a scientifically robust industry with support from the FDA for fast-tracking drug development -The clinical potential of psychedelics to treat illnesses ranging from mental illness to pain management and other nervous system disorders -Neo Kuma's focus on investing in early stage companies backed by sound science and building a strong founder network -Predictions that psychedelics as medication is here to stay, and the growing commercialization opportunities in the space